FSD is in the Path of Growing - look at the Science Section
Since 2010, there have been 19 approvals by the U.S. Food and Drug Administration, or FDA, for the treatment of pain, of which 11 were opioid variants, one was an extended release generic corticosteroid, five were variants of aspirin, and two were variants of other existing drugs.
In the area of neurological disorders, cannabis-based medicines have demonstrated safety, efficacy, and consistency sufficient for regulatory approval in multiple sclerosis and in rare forms of epilepsy, approved for these indications by the FDA in June 2018. Recently, positive developments using cannabinoids in a variety of difficult-to-treat neurological disorders have offered a significant and promising pathway to potential breakthroughs in the healthcare industry.
FSD is developing a portfolio of novel cannabinoid drug candidates designed to overcome the limitations of current treatment options for chronic pain and to present patients and physicians with better and safer treatment alternatives.